Duration of dual anti-platelet therapy - State of the art after the DAPT and PEGASUS-TIMI 54 trials.
Acta Cardiol
; 72(3): 256-264, 2017 Jun.
Article
em En
| MEDLINE
| ID: mdl-28636514
ABSTRACT
Dual anti-platelet therapy is prescribed in the setting of coronary heart disease for the prevention of stent thrombosis and acute thrombotic events. The optimal duration of dual anti-platelet therapy is still under debate as numerous trials have shown non-inferiority of a strategy of early cessation of one of the agents as compared to the standard practice whereas two larger trials have demonstrated benefit of prolonging dual anti-platelet therapy.
Palavras-chave
Texto completo:
1
Eixos temáticos:
Pesquisa_clinica
Base de dados:
MEDLINE
Assunto principal:
Inibidores da Agregação Plaquetária
/
Ensaios Clínicos Controlados Aleatórios como Assunto
/
Stents
/
Terapia Trombolítica
/
Reestenose Coronária
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article